{"ORPHApacket":[{"ORPHApacketID":"276402","date":"2019-12-06 02:10:33","version":"1.3.1 \/ 4.1.7 [2019-11-24] (orientdb version)","copyright":"Orphanet (c) 2019","ORPHA":"276402","Name":[{"lang":"en","label":"Limbic encephalitis with caspr2 antibodies"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_276402","DisorderType":[{"Name":[{"lang":"en","label":"Disease"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_377788"}],"SubClassOfList":[{"Disorder":[{"Name":[{"lang":"en","label":"Non-paraneoplastic limbic encephalitis"}],"ORPHA":"163918","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_163918"}]}],"TextSection":[{"Name":[{"lang":"en","label":"Definition"}],"Contents":"Limbic encephalitis with caspr2 antibodies is a rare neuroimmunological disorder characterized by the onset of cognitive deficits, psychiatric disturbances (e.g. personality changes), seizures, peripheral nerve hyperexcitability, dysautonomia, neuropathic pain, insomnia and weight loss, in association with detection of caspr2 antibodies in serum or cerebrospinal fluid, with or without underlying malignancies. Other features reported include blepharoclonus, myoclonic status epilepticus, and dyskinesia."}]}]}